{"id":481586,"title":"Notice: Multiple additions to the Prescription Drug List (PDL) [2022-06-17] - Canada.ca","sourceCode":"hc","sourceName":"Health Canada","language":"en","captureDate":"2026-01-06","captureTimestamp":"2026-01-06T17:02:14.511000+00:00","jobId":6,"originalUrl":"https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2022-06-17.html?wbdisable=true","snippet":"Notice: Multiple additions to the Prescription Drug List (PDL) June 17, 2022 Our file number: 22-107199-26 The purpose of this Notice of Amendment is to notify about the additions of amivantamab, belumosudil, bimekizumab, cariprazine, cilgavimab, lumasiran, pegvaliase and…","rawSnapshotUrl":"/api/snapshots/raw/481586","browseUrl":"https://replay.healtharchive.ca/job-6/20260106170214/https://www.canada.ca/en/health-canada/services/drugs-health-products/drug-products/prescription-drug-list/notices-changes/multiple-additions-2022-06-17.html?wbdisable=true#ha_snapshot=481586","mimeType":"text/html","statusCode":200,"captureBackend":"browsertrix","captureFidelity":"high"}